HZNP

Horizon Therapeutics Public Limited Company (HZNP) | Rumor.io

Horizon Therapeutics Public

HZNP

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about HZNP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 6

Amgen has completed its $28.7 billion acquisition of Horizon Therapeutics.
The acquisition was finalized after receiving final regulatory approval from the U.S. Federal Trade Commission.
Insider sales include $101.9 million worth of shares by Chairman, President and CEO Walbert Timothy P, and $27.3 million worth of shares by EVP and Chief Medical Officer Sherman Jeffrey W.

Generated by AI

Sentiment

Of the messages about HZNP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +11.53
Bearish	—	—	—	0% -11.53

Bullish· Dec 13

$HZNP has been a successful Cinderella story, transitioning from a spec pharma to innovative biopharma through focused business development and acquisitions.
The company's acquisition by $AMGN for $28.7B at a 20% premium marks a well-deserved win for shareholders and adds immediate, substantial growth.
$HZNP's transition to its roots in rare disease M&A has been a key driver of its success, with the company poised for continued growth in this area.

Bearish· May 16

The FTC's block on the $HZNP acquisition by $AMGN may lead to smaller deals and less spending by pharmaceutical companies.
The FTC's decision may have a broader impact on the drug space, particularly with regards to pricing and PBM issues.
The weak 1Q23 earnings of $HZNP, particularly with regards to Tepezza revenue, may be used as an excuse for $AMGN to exit the deal.

Generated by AI

Topics

Of the messages about HZNP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Nov 2

Horizon Therapeutics Public Limited Company (HZNP) reported Q3 2022 earnings of $1.25 EPS and $925.36M in revenue, beating expectations.
The company increased its FY 2022 guidance to $3.59 billion-$3.61 billion in revenue, and also raised its net sales and adjusted EBITDA guidance.
HZNP's earnings beat the Estimize EPS consensus by 18 cents and the Estimize revenue consensus by $34.48 million, with the stock experiencing an 11.3% move.

Analysts· Dec 13

Wells Fargo downgraded HZNP from Overweight to Equal-Weight and lowered the price target from $118 to $116.50.
SVB Leerink downgraded HZNP from Outperform to Market Perform and raised the price target from $88 to $116.50.
Guggenheim downgraded HZNP from Buy to Neutral and raised the price target from $98 to $116.50.

Announcements· Oct 6

Amgen ($AMGN) has completed its $28.7 billion acquisition of Horizon Therapeutics ($HZNP) after receiving final regulatory approval.
The acquisition was a significant one, with Amgen acquiring Horizon Therapeutics for $27.8 billion.
Insider trading activity has been reported, with several executives disposing of their shares of $HZNP following the acquisition.

Controversies· Sep 1

The FTC has reached a deal with Amgen, allowing the company's $27.8 billion purchase of Horizon Therapeutics to move forward, with Amgen prohibited from leveraging its drug portfolio to disadvantage rivals.
The settlement requires Amgen to seek prior approval before acquiring related products, and Horizon Therapeutics is expected to close the deal in 4Q, with Amgen now clear to acquire the company.
The FTC's lawsuit aimed at stopping the transaction was suspended in August, and the agency has now allowed the deal to proceed, with some critics describing the FTC's complaint as "weak" but others seeing the settlement as a safeguard against the agency's "bundling" concerns.

Technical Analysis· Nov 6

The Parabolic SAR indicator has switched to up on HZNP, indicating a potential buy signal, with momentum rising.
Two bullish signals have been triggered on HZNP, with a Support/Resistance level of 14.16/14.82.
The author is considering entering a long position on HZNP based on the two bullish signals.

Generated by AI

Community

Of the messages about HZNP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	94.15%
Newcomers	—	—	—	5.85%

Regulars· Sep 1

Amgen has agreed to settle with the FTC, allowing its $27.8 billion purchase of Horizon Therapeutics to move forward, with the company prohibited from leveraging its drug portfolio to disadvantage rivals.
The settlement includes provisions that will require Amgen to seek prior approval before acquiring related products, and Horizon Therapeutics is expected to jointly file stipulated proposed orders to dismiss the PI motion and dissolve the TRO.
Amgen and Horizon Therapeutics expect to quickly seek the final approvals required under Irish law to close the deal, which has been delayed due to the need for Irish high court approval.

Newcomers· Oct 6

Analysts are setting price targets for $HZNP, with some expecting it to increase in value, while others are shorting the stock and waiting for the puts to expire or delist.
Several insiders have recently sold large amounts of $HZNP shares, with some disposing of nearly 100% of their holdings, leading to trading halts and increased market activity.
The acquisition of Horizon Therapeutics by Amgen has been completed, with the company receiving regulatory approval from the U.S. Federal Trade Commission, and the combined entity is now trading under the $AMGN ticker.

Generated by AI

Also Discussed

Investors talking about HZNP also mention

#	Name	Attention
1	Amarin Corporation plc ADRAMRN	0%+0
2	NAVB - Navidea Biopharmaceuticals, Inc.	——
3	Perrigo Company plcPRGO	0%0
4	FOLD - Amicus Therapeutics, Inc.	——
5	Amgen Inc.AMGN	0.01%+0
6	Acadia Pharmaceuticals Inc.ACAD	0%+0
7	iShares Biotechnology ETFIBB	0.01%0
8	Supernus Pharmaceuticals, Inc.SUPN	0%new
9	Exelixis Inc.EXEL	0%-0.03
10	Halozyme Therapeutics Inc.HALO	0%0